INSMED Inc

INSM 10-Q · Q1 2026
API behind this page

INSM Q1 2026 request

Playground key active
Request URL /api/financials?ticker=INSM&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 305,964 92,823 +229.6%
Show Product Lines breakouts
ARIKAYCE external R&D expenses 98,110 92,823 +5.7%
ARIKAYCE external R&D expenses · Non Us 35,226 28,548 +23.4%
ARIKAYCE external R&D expenses · US 62,884 64,275 -2.2%
BRINSUPRI 207,854 — —
BRINSUPRI · Non Us 672 — —
BRINSUPRI · US 207,182 — —
Show Business Segments breakouts
Reportable Segment 305,964 92,823 +229.6%
Show Geography breakouts
Non Us 35,898 28,548 +25.7%
US 270,066 64,275 +320.2%
Cost of Revenue 47,420 21,278 +122.9%
Show Business Segments breakouts
Reportable Segment 47,420 21,278 +122.9%
Total Costs & Expenses 459,284 340,963 +34.7%
Research & Development 209,485 152,577 +37.3%
Show Product Lines breakouts
ARIKAYCE external R&D expenses · Reportable Segment 8,622 12,121 -28.9%
Brensocatib external R&D expenses · Reportable Segment 18,484 20,661 -10.5%
Other external R&D expenses · Reportable Segment 32,678 28,083 +16.4%
TPIP external R&D expenses · Reportable Segment 37,341 9,153 +308.0%
Selling, General & Administrative 247,259 147,545 +67.6%
Operating Income -153,320 -248,140 +38.2%
Interest Expense -20,082 -21,569 +6.9%
Show Business Segments breakouts
Reportable Segment -20,082 -21,569 +6.9%
Other Non-Operating Income (Expense) -736 132 -657.6%
Income Before Taxes -162,098 -255,671 +36.6%
Income Tax Expense (Benefit) 1,465 912 +60.6%
Show Business Segments breakouts
Reportable Segment 1,465 912 +60.6%
Comprehensive Income -165,020 -255,196 +35.3%
Other Comprehensive Income -1,457 1,387 -205.0%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -1,457 1,387 -205.0%
EPS (Basic) -0.76 -1.42 +46.5%
EPS (Diluted) -0.76 -1.42 +46.5%
Wtd Avg Shares (Basic) 215,468 180,860 +19.1%
Wtd Avg Shares (Diluted) 215,468 180,860 +19.1%
Net Income Loss Available To Common Stockholders Basic -163,563 -256,583 +36.3%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 582,188 403,247 +44.4%
Marketable Securities (Current) 641,326 796,204 -19.5%
Accounts Receivable 178,555 47,746 +274.0%
Inventory 132,909 100,713 +32.0%
Prepaid Expenses & Other Current Assets 78,195 54,782 +42.7%
Total Current Assets 1,613,173 1,402,692 +15.0%
Non-Current Assets
Property, Plant & Equipment 102,846 88,358 +16.4%
Operating Lease Right-of-Use Assets 14,004 10,832 +29.3%
Intangible Assets 95,570 57,389 +66.5%
Show Product Lines breakouts
AstraZeneca milestone · Licensing Agreements 43,233 — —
PARI milestones · Licensing Agreements 911 — —
Show Finite Lived Intangible Assets By Major Class breakouts
Acquired ARIKAYCE R&D 21,826 26,676 -18.2%
In Process Research And Development 29,600 29,600 0.0%
Goodwill 136,110 136,110 0.0%
Total Assets 2,075,863 1,802,735 +15.2%
Other Assets
Finance Lease Right Of Use Asset 14,883 17,595 -15.4%
Other Assets 99,277 89,759 +10.6%
Current Liabilities
Accounts Payable And Accrued Liabilities Current 352,555 232,674 +51.5%
Finance Lease Liability Current 3,446 3,054 +12.8%
Operating Lease Liability Current 5,007 3,505 +42.9%
Total Current Liabilities 361,008 239,233 +50.9%
Accounts Payable 73,380 57,683 +27.2%
Non-Current Liabilities
Long-Term Debt 542,215 — —
Accrued Royalties Current And Noncurrent 162,137 162,508 -0.2%
Show Debt Instrument breakouts
Royalty Agreements · Secured Debt 164,086 164,981 -0.5%
Business Combination Contingent Consideration Liability Noncurrent 270,310 159,900 +69.0%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level3 · Motus 270.3 159.9 +69.0%
Finance Lease Liability Noncurrent 19,820 23,266 -14.8%
Operating Lease Liabilities 9,837 8,480 +16.0%
Other Non-Current Liabilities 5,684 5,121 +11.0%
Total Liabilities 1,371,011 1,703,576 -19.5%
Long-Term Debt 546,770 1,121,688 -51.3%
Stockholders' Equity
Common Stock 2,165 1,819 +19.0%
Additional Paid-In Capital 6,502,938 4,714,742 +37.9%
Retained Earnings -5,800,255 -4,616,500 -25.6%
Accumulated Other Comprehensive Income 4 -902 +100.4%
Total Stockholders' Equity 704,852 99,159 +610.8%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 4 -902 +100.4%
Additional Paid In Capital 6,502,938 4,714,742 +37.9%
Common Stock 2,165 1,819 +19.0%
Retained Earnings -5,800,255 -4,616,500 -25.6%
Total Liabilities & Equity 2,075,863 1,802,735 +15.2%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Net Income -163,563 -256,583 +36.3%
Show Business Segments breakouts
Reportable Segment -163,563 -256,583 +36.3%
Show Equity Components breakouts
Retained Earnings -163,563 -256,583 +36.3%
Depreciation 2,934 1,883 +55.8%
Amortization Of Intangible Assets 2,081 1,263 +64.8%
Show Product Lines breakouts
AstraZeneca milestone · Licensing Agreements 818 — —
PARI milestones · Licensing Agreements 51 — —
Show Business Segments breakouts
Reportable Segment 2,081 1,263 +64.8%
Show Finite Lived Intangible Assets By Major Class breakouts
Acquired ARIKAYCE R&D 1,212 1,212 0.0%
Stock-Based Compensation 45,754 39,262 +16.5%
Amortization Of Financing Costs And Discounts 1,382 1,822 -24.1%
Other Noncash Expense 5,114 5,023 +1.8%
Accretion Of Debt Discount Marketable Securities -6,513 -8,332 +21.8%
Finance Lease Right Of Use Asset Amortization 678 678 0.0%
Noncash Operating Lease Expense 567 686 -17.3%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 -46,961 18,300 -356.6%
Show Business Segments breakouts
Reportable Segment -46,961 18,300 -356.6%
Change in Accounts Receivable -38,190 5,361 -812.4%
Change in Inventory -1,886 -1,021 -84.7%
Change in Prepaid & Other Assets 12,594 -16,941 +174.3%
Increase Decrease In Other Noncurrent Assets -2,357 10,168 -123.2%
Increase Decrease In Accounts Payable And Accrued Liabilities -33,875 -61,490 +44.9%
Increase Decrease In Other Operating Liabilities -497 -2,167 +77.1%
Net Cash from Operations -222,738 -262,088 +15.0%
Investing Activities
Capital Expenditures -3,480 -10,070 +65.4%
Payment Of Milestone -15,000 — —
Proceeds From Sale And Maturity Of Marketable Securities 284,000 721,000 -60.6%
Net Cash from Investing 265,520 80,412 +230.2%
Financing Activities
Proceeds From Stock Options Exercised 30,313 29,704 +2.1%
Finance Lease Principal Payments -799 -706 -13.2%
Net Cash from Financing 29,514 28,998 +1.8%
Amortization of Financing Costs 1,382 1,822 -24.1%
Show Debt Instrument breakouts
Royalty Agreements · Secured Debt 131 — —
Supplemental
Interest Paid 13,122 13,122 0.0%
Income Taxes Paid 2,940 2,176 +35.1%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -553 895 -161.8%
Net Change in Cash 71,743 -151,783 +147.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 582,188 403,247 +44.4%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key